(Q38042570)

27 August 2017

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma (English)

1 reference

27 August 2017

Susan L Cohn

4

0 references

Ravi Salgia

5

object named as

Ravi Salgia

1 reference

27 August 2017

Andres Morales La Madrid

1

1 reference

27 August 2017

Nicholas Campbell

2

1 reference

27 August 2017

Sonali Smith

3

1 reference

27 August 2017

language of work or name

1 reference

12 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

7

1 reference

27 August 2017

3

1 reference

27 August 2017

199-210

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-012-0227-8

27 August 2017

0 references

cites work

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Emerging importance of ALK in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

MET pathway as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Pathobiology of ALK+ anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Brentuximab vedotin in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Oncogenic mutations of ALK in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Treating ALK-positive lung cancer--early successes and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

A novel classification of lung cancer into molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

EML4-ALK fusion lung cancer: a rare acquired event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

A novel KIF5B-ALK variant in nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0227-8

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 January 2018

1 reference

12 December 2020

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

1 reference

12 December 2020

Cytogenetic features of human neuroblastomas and cell lines.

1 reference

12 December 2020

Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

1 reference

12 December 2020

Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.

1 reference

12 December 2020

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

12 December 2020

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

1 reference

12 December 2020

A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation

1 reference

12 December 2020

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

1 reference

12 December 2020

1 reference

12 December 2020

Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis

1 reference

12 December 2020

Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3

1 reference

12 December 2020

Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.

1 reference

12 December 2020

10.1007/S11523-012-0227-8

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference